Abstract:The epidemiological burden of liver steatosis associated with metabolic diseases is continuously growing worldwide and in all age classes. This condition generates possible progression of liver damage (i.e., inflammation, fibrosis, cirrhosis, hepatocellular carcinoma) but also independently increases the risk of cardio-metabolic diseases and cancer. In recent years, the terminological evolution from "nonalcoholic fatty liver disease" (NAFLD) to "metabolic dysfunction-associated fatty liver disease" (MAFLD) and, finally, "metabolic dysfunction-associated steatotic liver disease" (MASLD) has been paralleled by increased knowledge of mechanisms linking local (i.e., hepatic) and systemic pathogenic pathways. As a consequence, the need for an appropriate classification of individual phenotypes has been oriented to the investigation of innovative therapeutic tools. Besides the well-known role for lifestyle change, a number of pharmacological approaches have been explored, ranging from antidiabetic drugs to agonists acting on the gut–liver axis and at a systemic level (mainly farnesoid X receptor (FXR) agonists, PPAR agonists, thyroid hormone receptor agonists), anti-fibrotic and anti-inflammatory agents. The intrinsically complex pathophysiological history of MASLD makes the selection of a single effective treatment a major challenge, so far. In this evolving scenario, the cooperation between different stakeholders (including subjects at risk, health professionals, and pharmaceutical industries) could significantly improve the management of disease and the implementation of primary and secondary prevention measures. The high healthcare burden associated with MASLD makes the search for new, effective, and safe drugs a major pressing need, together with an accurate characterization of individual phenotypes. Recent and promising advances indicate that we may soon enter the era of precise and personalized therapy for MASLD/MASH.

Spatial genomics: mapping human steatotic liver disease

Manipulating the Gut Microbiome to Alleviate Steatotic Liver Disease: Current Progress and Challenges

A prognostic molecular signature of hepatic steatosis is spatially heterogeneous and dynamic in human liver

A data-driven approach to decode metabolic dysfunction-associated steatotic liver disease

Understanding Macrophage Complexity in Metabolic Dysfunction-Associated Steatotic Liver Disease: Transitioning from the M1/M2 Paradigm to Spatial Dynamics

Single-cell transcriptomics stratifies organoid models of metabolic dysfunction-associated steatotic liver disease

Genetics of Metabolic Dysfunction-associated Steatotic Liver Disease: The State of the Art Update

Gut Microbes, Diet, and Genetics as Drivers of Metabolic Liver Disease: A Narrative Review Outlining Implications for Precision Medicine

A comprehensive framework for managing metabolic dysfunction-associated steatotic liver disease: analyzing novel risk factors and advances in nanotechnology-based treatments and diagnosis

Spatial metabolomics and its application in the liver

Applying Proteomics in Metabolic Dysfunction-Associated Steatotic Liver Disease: from Mechanism to Biomarkers

Diagnostics and omics technologies for the detection and prediction of metabolic dysfunction-associated steatotic liver disease-related malignancies

Novel insights into metabolic‐associated steatotic liver disease preclinical models

Spatial Omics Reveals that Cancer-Associated Glycan Changes Occur Early in Liver Disease Development in a Western Diet Mouse Model of MASLD

Metabolic-associated steatotic liver disease and hepatocellular carcinoma

Exploring the Multifaceted Landscape of MASLD: A Comprehensive Synthesis of Recent Studies, from Pathophysiology to Organoids and Beyond

MASLD and the Development of HCC: Pathogenesis and Therapeutic Challenges

From Pathogenesis to Current Therapeutic Options

Spatial transcriptomics of healthy and fibrotic human liver at single-cell resolution

Maladaptive regeneration and metabolic dysfunction associated steatotic liver disease: Common mechanisms and potential therapeutic targets

Spatial multi-omics characterizes GPR35-relevant lipid metabolism signatures across liver zonation in MASLD